Drug Profile
Cibisatamab - Roche
Alternative Names: CEA-CD3 TCB; CEA-TCB; RG-7802; RO-6958688Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Carcinoembryonic antigen inhibitors; CD3 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
- Phase I Colorectal cancer; Solid tumours
Most Recent Events
- 13 Mar 2024 Roche completes a phase I trial in Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA, Denmark, France, and Spain (IV) (NCT03866239)
- 24 Oct 2023 Suspended - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Recurrent) in Japan (IV)
- 24 Oct 2023 Suspended - Phase-I for Solid tumours (Late-stage disease, Monotherapy, Recurrent) in Japan (IV)